Metastatic Colorectal Cancer Drugs Market to Grow with a CAGR of 4.48% through 2028
Rising incidence of colorectal cancer is expected to
drive the Global Metastatic Colorectal Cancer Drugs Market growth in the
forecast period, 2024-2028.
According to TechSci Research report, “Metastatic
Colorectal Cancer Drugs Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Metastatic
Colorectal Cancer Drugs Market stood at USD 3.12 billion in 2022 and is
anticipated to grow with a CAGR of 4.48% in the forecast period, 2024-2028. The
global Metastatic Colorectal Cancer Drugs (mCRC) market is experiencing
significant growth and transformation, driven by a confluence of factors that
are reshaping the landscape of cancer treatment. One of the foremost drivers of
growth in the mCRC market is the continual advancement in treatment modalities.
Over the years, there has been a paradigm shift from traditional chemotherapy
to more targeted and immunotherapy-based approaches. Monoclonal antibodies like
Bevacizumab and Cetuximab have gained prominence, targeting specific molecular
pathways involved in cancer growth. These drugs have shown significant efficacy
in delaying disease progression and improving overall survival rates.
Additionally, the development of tyrosine kinase
inhibitors, such as Regorafenib and Lonsurf, has provided new options for
patients who have exhausted standard treatment options. These drugs work by
inhibiting specific enzymes involved in tumor growth, offering hope to mCRC
patients who previously had limited therapeutic choices. The advent of immunotherapy has been a
game-changer in the field of oncology, including mCRC. Immune checkpoint
inhibitors like Pembrolizumab and Nivolumab have demonstrated remarkable
results in clinical trials, as they harness the body's immune system to target
and destroy cancer cells. These therapies hold the potential to bring about
durable responses in a subset of mCRC patients, making them an exciting area of
research and investment.
Personalized medicine has gained prominence in cancer
treatment, and mCRC is no exception. Understanding the genetic and molecular
makeup of a patient's tumor is crucial in tailoring treatment regimens.
Biomarker development, such as microsatellite instability-high (MSI-H) or
mismatch repair deficiency (dMMR) status, helps identify patients who are
likely to respond to specific therapies like immune checkpoint inhibitors.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Metastatic Colorectal Cancer Drugs Market.”
The global incidence of colorectal cancer has been
steadily rising, with a notable increase in developed nations. This trend is
primarily attributed to lifestyle factors, including diet, obesity, and
sedentary behavior. As populations age, the risk of developing colorectal
cancer increases, further driving the demand for mCRC treatments. This
demographic shift underscores the urgency for effective treatments and has
prompted pharmaceutical companies to invest heavily in research and development
to address this growing patient population.
The Global Metastatic Colorectal Cancer Drugs Market
is segmented into Drug Class, Treatment, End-user, regional distribution, and
company.
Based on the Type, the Anti-VEGF (Vascular Endothelial
Growth Factor) Therapies emerged as the dominant segment in the global market
for Global Metastatic Colorectal Cancer Drugs Market in 2022. Anti-VEGF
(Vascular Endothelial Growth Factor) Therapies are the most widely used in the
treatment of metastatic colorectal cancer, thus creating a high demand in the
Global Metastatic Colorectal Cancer Drugs Market. The use of Anti-VEGF therapies
has become standard practice in combination with chemotherapy for the treatment
of metastatic colorectal cancer. These drugs have demonstrated effectiveness in
improving progression-free survival and overall survival in clinical trials,
making them a cornerstone of mCRC treatment.
Based on the Treatment, Chemotherapy emerged as the
dominant player in the global market for Global Metastatic Colorectal Cancer
Drugs Market in 2022. Chemotherapy has a long history of use in cancer
treatment and has demonstrated efficacy in controlling tumor growth and
extending the survival of mCRC patients. While it may not be curative for
metastatic disease, it is often the first-line treatment to slow disease
progression. Chemotherapy is suitable for a wide range of mCRC patients, regardless
of specific genetic mutations or molecular characteristics. It can be used as
an initial treatment option before more targeted therapies are considered, and
it remains relevant throughout the treatment journey.
Chemotherapy is frequently used in combination with
other treatment modalities, such as targeted therapies or immunotherapies.
These combination approaches have shown promise in improving treatment
outcomes, further solidifying the role of chemotherapy. Chemotherapy can help
alleviate symptoms associated with metastatic colorectal cancer, such as pain
and discomfort. It plays a vital role in enhancing the quality of life for
patients, which is an essential aspect of cancer care.
Based on the End User, the Hospitals & Clinics emerged
as the dominant player in the global market for Global Metastatic Colorectal
Cancer Drugs Market in 2022. Hospitals, especially those with specialized cancer
centers, offer comprehensive care for cancer patients. This includes a wide
range of services such as diagnostic tests, surgery, chemotherapy, radiation
therapy, targeted therapies, immunotherapies, and supportive care, all of which
are essential in the management of metastatic colorectal cancer. Hospitals often have specialized oncology
departments staffed with multidisciplinary teams of oncologists, surgeons,
radiologists, and nurses who have extensive experience in cancer care. This
expertise is crucial in providing optimal treatment and support for Metastatic
Colorectal Cancer Drugs patients.
North America emerged as the dominant player in the
global Metastatic Colorectal Cancer Drugs Market in 2022, holding the largest market share.
Colorectal cancer is one of the most common cancer types in North America. The
region has a higher incidence of colorectal cancer compared to other parts of
the world, contributing to a substantial patient population in need of
treatment for metastatic disease. North America boasts a well-developed and advanced
healthcare infrastructure, which includes state-of-the-art hospitals,
specialized cancer centers, and a large network of healthcare providers. This
infrastructure supports the efficient diagnosis and treatment of metastatic
colorectal cancer, attracting patients from both within the region and abroad.
Many
countries in North America, including the United States and Canada, have
well-established healthcare insurance systems that provide coverage for cancer
treatments. This reduces the financial burden on patients and ensures that they
can access and afford the necessary care.
Major companies operating in Global Metastatic
Colorectal Cancer Drugs Market are:
- Amgen Inc.
- EMD Serono
- Eli Lilly and
company
- Genentech
- Novartis AG
- Pfizer Inc.
- F. Hoffmann-La Roche
Ltd
- Sanofi
- Suzhou Zelgen Biopharmaceuticals
- Taiho Oncology
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global Metastatic
Colorectal Cancer Drugs Market is poised for significant growth in the coming
years, driven by several key factors. Firstly, the rising incidence of
colorectal cancer, particularly in developed countries, is expected to
contribute to a larger patient population seeking treatment for metastatic
disease. Secondly, advancements in cancer research and drug development have
led to the introduction of innovative therapies, including immunotherapies and
targeted drugs, providing more treatment options for patients and boosting
market growth. Additionally, the trend toward precision medicine and
biomarker-driven therapies is expected to play a pivotal role in tailoring
treatments to individual patients, improving outcomes, and fueling market
expansion. Furthermore, collaborations between pharmaceutical companies and
research institutions, coupled with a surge in clinical trial activities, are
likely to yield novel treatment approaches and therapies, enhancing the
market's competitiveness.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Anti-EGFR
(Epidermal Growth Factor Receptor) Inhibitors, Anti-VEGF (Vascular Endothelial
Growth Factor) Therapies, Anti-HER2 (Human Epidermal Growth Factor Receptor 2)
Therapies, Immune Checkpoint Inhibitors, Others), By Treatment (Chemotherapy,
Targeted Therapies, Immunotherapies, Others), By End-user (Hospitals &
Clinics, Ambulatory Care Centres, Others)
By Region and Competition”, has evaluated the future growth potential of Global
Metastatic Colorectal Cancer Drugs Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Metastatic Colorectal Cancer Drugs Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com